Seeking Alpha

More on Biogen (BIIB) Q2: net profit +34% to $386.8M, helped by strong sales of...

More on Biogen (BIIB) Q2: net profit +34% to $386.8M, helped by strong sales of multiple-sclerosis treatment Avonex and cancer drug Rituxan, and reflecting a $50M charge last year. Ups FY EPS guidance to $6.20 from $6.15 prior, vs. consensus of 6.22. Shares flat at $139.28, although they had been as high as $142.68. BIIB had gained 27% YTD through yesterday.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|